Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $206,930.22 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 7,522 shares of the business’s stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $27.51, for a total value of $206,930.22. Following the completion of the sale, the insider now owns 1,069,887 shares in the company, valued at $29,432,591.37. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Enliven Therapeutics Trading Down 4.4 %

Enliven Therapeutics stock opened at $26.97 on Friday. The firm has a market capitalization of $1.27 billion, a PE ratio of -13.97 and a beta of 1.10. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $28.62. The firm has a 50-day moving average price of $23.34 and a 200-day moving average price of $22.22.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in Enliven Therapeutics in the third quarter worth about $256,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics during the second quarter worth $322,000. Marshall Wace LLP purchased a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at $4,489,000. First Turn Management LLC purchased a new stake in Enliven Therapeutics in the second quarter valued at $9,657,000. Finally, Nicholas Investment Partners LP purchased a new stake in shares of Enliven Therapeutics in the second quarter worth about $1,310,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.